A Multi-Center, Open-Label, Single Arm and Flexible Dose Study of the Effectiveness and Safety of Oral Use Lurasidone HCl Tablet (LATUDA®) for 40-160 mg/Day in Subjects With Schizophrenia
Phase of Trial: Phase IV
Latest Information Update: 26 Sep 2019
Price : $35 *
At a glance
- Drugs Lurasidone (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Standard Chemical & Pharmaceutical Company
- 22 Sep 2019 Planned End Date changed from 1 Aug 2019 to 1 Dec 2019.
- 22 Sep 2019 Planned primary completion date changed from 1 Aug 2019 to 1 Dec 2019.
- 04 Oct 2018 Status changed from not yet recruiting to recruiting.